SCHEMBL1628656

SCHEMBL1628656

CCC/C=C/c1cc(CC(=O)OC)cc(OCc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
PKM P14618 1/20 0.49
AKR1C3 P42330 2/20 0.47
AKR1C2 P52895 2/20 0.47
CYP1A1 P04798 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP19A1 P11511 1/20 0.45
FFAR1 O14842 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
GSK3B P49841 1/20 0.43
BACE1 P56817 1/20 0.43
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LTB4R Q15722 3/20 0.41
LTB4R2 Q9NPC1 3/20 0.41
BCHE P06276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29424405 1.00 KDM4E (0.49) KDM4EALDH1A1PKMAKR1C3AKR1C2
SCHEMBL3725341 0.90 KDM4E (0.52) KDM4EALDH1A1PKMAKR1C3AKR1C2
SCHEMBL3725344 0.90 KDM4E (0.52) KDM4EALDH1A1PKMAKR1C3AKR1C2
SCHEMBL490786 0.82 MEN1 (0.59) ALDH1A1LMNAMEN1KMT2ALTB4R
SCHEMBL16050530 0.82 HSP90AB1 (0.49) KDM4EALDH1A1PKMAKR1C3BACE1
SCHEMBL9204780 0.82 LTB4R (0.55) KDM4EALDH1A1LMNAMEN1KMT2A
SCHEMBL16050532 0.82 HSP90AB1 (0.49) KDM4EALDH1A1PKMAKR1C3BACE1
SCHEMBL16050553 0.80 PTGER4 (0.41) KDM4EALDH1A1PKMLMNABCHE
SCHEMBL16050552 0.80 PTGER4 (0.41) KDM4EALDH1A1PKMLMNABCHE
SCHEMBL11891941 0.80 MEN1 (0.50) ALDH1A1GSK3BBACE1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Liminal Biosciences Limited (GB) 2021-11-30 US disclosed
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION LIMINAL BIOSCIENCES LTD (GB) 2021-03-25 US disclosed
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof PROMETIC BIOSCIENCES, INC. (CA) 2021-01-07 US disclosed
EP-3443957-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER LIMINAL BIOSCIENCES LTD (GB) 2020-11-25 EP disclosed
US-10815183-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2020-10-27 US disclosed
US-20200237693-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS LIMINAL BIOSCIENCES INC (GB) 2020-07-30 US disclosed
US-10391073-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration PROMETIC PHARMA SMT LIMITED (GB) 2019-08-27 US disclosed
EP-3443957-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC PHARMA SMT LIMITED (GB) 2019-02-20 EP disclosed
US-20180162799-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC PHARMA SMT LIMITED (GB) 2018-06-14 US disclosed
US-20180162799-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC PHARMA SMT LIMITED (GB) 2018-06-14 US disclosed
US-9114118-B2 Compounds and compositions for the treatment of cancer PROMETIC BIOSCIENCES INC. (CA) 2015-08-25 US disclosed
US-20150094372-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF Liminal Biosciences Limited (GB) 2015-04-02 US disclosed
US-20150094372-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF Liminal Biosciences Limited (GB) 2015-04-02 US disclosed
US-8927765-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC BIOSCIENCES INC. (CA) 2015-01-06 US disclosed
US-8927765-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC BIOSCIENCES INC. (CA) 2015-01-06 US disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162799-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION COL1A1, CCNH, COL2A1 KDM4E 1096/4885ALDH1A1 129/4885PKM 2210/4885
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer DCK, TOP2B, TOP2A KDM4E 460/4885ALDH1A1 467/4885PKM 61/4885
US-20200237693-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS ADIPOR1, ADIPOR2, FN1 KDM4E 1479/4885ALDH1A1 1129/4885PKM 4187/4885
US-10391073-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration CCNH, COL1A1, COL2A1 KDM4E 1142/4885ALDH1A1 165/4885PKM 2383/4885
US-10815183-B2 Substituted aromatic compounds and pharmaceutical uses thereof TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885
US-20150094372-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis ADIPOR1, ADIPOR2, FN1 KDM4E 1479/4885ALDH1A1 1129/4885PKM 4187/4885
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.